Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial

The Lancet Oncology

Volumn 14, Issue 8, 2013, Pages 777-786

  Wu, Yi Long ^a   Lee, Jin Soo ^o   Thongprasert, Sumitra ^x   Yu, Chong Jen ^s   Zhang, Li ^f   Ladrera, Guia ^q   Srimuninnimit, Vichien ^y   Sriuranpong, Virote ^z   Sandoval Tan, Jennifer ^p   Zhu, Yunzhong ^b   Liao, Meilin ^c   Zhou, Caicun ^d   Pan, Hongming ^e   Lee, Victor ^j   Chen, Yuh Min ^t,u   Sun, Yan ⁱ   Margono, Benjamin ^m   Fuerte, Fatima ^r   Chang, Gee Chen ^v,w   Seetalarom, Kasan ^aa   Wang, Jie ^g   Cheng, Ashley ^k   Syahruddin, Elisna ^l   Qian, Xiaoping ^h   Ho, James ^j   Kurnianda, Johan ⁿ   Liu, Hsingjin Eugene ^u   Jin, Kate ^ac   Truman, Matt ^ac   Bara, Ilze ^ad   Mok, Tony ^ab   more..

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANGHAI CHEST HOSPITAL   (China)

^d SHANGHAI PULMONARY HOSPITAL   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^g PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^h THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

ⁱ PEKING UNION MEDICAL COLLEGE   (China)

^j QUEEN MARY HOSPITAL   (Hong Kong)

^k PRINCESS MARGARET HOSPITAL   (Hong Kong)

^l Indonesia Persahabatan Hospital   (Indonesia)

^m AIRLANGGA UNIVERSITY   (Indonesia)

ⁿ Dr Sardjito Hospital   (Indonesia)

^o National Cancer Center   (South Korea)

^p PHILIPPINE GENERAL HOSPITAL   (Philippines)

^q Lung Centre of the Philippines   (Philippines)

^r Rizal Medical Centre   (Philippines)

^s NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^t TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^u TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^v NATIONAL YANG MING UNIVERSITY   (Taiwan)

^w TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^x Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^y MAHIDOL UNIVERSITY   (Thailand)

^z KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^aa PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^ab CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^ac Roche Products Pty Ltd   (Australia)

^ad F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PEMETREXED; PLACEBO; TAXANE DERIVATIVE;

ACNE; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL STUDY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DERMATITIS ACNEIFORM; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRY SKIN; DYSPNEA; EGFR GENE; FATIGUE; FEMALE; GASTROENTERITIS; GENE MUTATION; HEMOPTYSIS; HUMAN; INSOMNIA; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SEPSIS; STOMATITIS; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84879784343     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70254-7     Document Type: Article

References (34)

1. Wakelee H, Belani C Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005, 10:1-10.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
4. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
6. Rosell R, Carcerency E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica.
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
8. Han JY, Park K, Kim SW, et al. First-SIGNAL: First-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128. for the West Japan Oncology Group.
10. Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012, 77:371-375.
11. Xu C, Zhou Q, Wu YL Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature-based meta-analysis. J Hematol Oncol 2012, 5:62-77.
12. Giaccone G, Herbst R, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial- INTACT 1. J Clin Oncol 2004, 22:785-794.
13. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004, 23(suppl):617. for the TALENT Study Investigators, (abstr 7010).
14. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
15. Gumerlock P, Pryde BJ, Kimura T, et al. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2003, 22(suppl):662. (abstr 2661).
16. Li T, Ling Y-H, Goldman ID, Perez-Soler R Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007, 13:3413-3422.
17. Cheng H, An S-H, Zhang X-C, et al. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemother Pharmacol 2011, 67:637-646.
18. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:5080-5087.
19. Aerts JG, Codrington H, Burgers S, et al. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small cell lung cancer patients: the NVALT-10 study. Ann Oncol 2012, 23(suppl 9):ixe21. (abstr LBA29).
20. Lee D, Lee J, Kim S, et al. A randomized phase 2 study of erlotinib plus pemetrexed vs erlotinib or pemetrexed alone as second-line treatment for never-smoker patients with non-squamous advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012, 23(suppl 9):ix400. (abstr 1225O).
21. Hirsch F, Kabbinavar F, Eisen T, et al. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3567-3573.
22. Aerts JG, Codrington H, Burgers S, et al. A randomized phase II study comparing erlotinib (E) versus alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 study. Ann Oncol 2012, (suppl 9):ixe21. (abstr LBA29).
23. Lee DH, Lee JS, Kim SW, et al. A randomized phase 2 study of erlotinib plus pemetrexed ve erlotinib or pemetrexed alone as second-line treatment for never-smoker patients with non-squamous advanced non-small cell lung cancer (NSCLC). Ann Oncol 2012, 23(suppl 9):ix400. (abst 1225O).
24. Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib with cisplatin plus docetaxel as first-line treatment for patients with non-small cell lung cancer harbouring mutations of epidermal growth factor receptor. Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7521.
25. Zhou C, Wu Y-L, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012, 30(suppl). abstr 7520.
26. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
27. Chen G, Feng J, Zhou C, et al. Quality of Life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 2013, published online March 1. 10.1093/annonc/mdt012.
28. Yang J, Schuler M, Yamamoto N, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung haboring EGFR-activating mutations. Proc Am Soc J Clin Oncol 2012, 30(suppl). abstr LBA7500.
29. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529. on behalf of the SATURN investigators.
30. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind, randomised phase 3 trial. Lancet Oncol 2012, 13:466-475. on behalf of the INFORM investigators.
31. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
32. Chen ZY, Zhong WZ, Zhang XC, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012, 17:978-985.
33. Boni C, Tiseo M, Boni L, et al. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer 2012, 106:658-665.
34. Weissman CH, Reynolds CH, Neubauer MA, et al. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6:358-364.